SAB Biotherapeutics ( NASDAQ: SABS ) on Thursday announced that, effective June 4, its Chief Financial Officer Michael King will be departing the company to accept a role as CEO at a privately-held oncology company. The company said Mark Conley, SAB’s current Vice President of Finance, will continue supporting SAB as interim CFO. SABS +2.
65% after hours to $2.71. Source: Press Release More on SAB Biotherapeutics Seeking Alpha’s Quant Rating on SAB Biotherapeutics Historical earnings data for SAB Biotherapeutics Financial information for SAB Biotherapeutics.